Pliant Therapeutics Stock

pliantrx.comHealthcare / BioTech & PharmaFounded: 2016

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Pliant Therapeutics before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Pliant Therapeutics Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Pliant Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
Funding Round Details are not yet available for this company.

Leadership & Board

Leadership

Bernard Coulie MD
Chief Executive Officer, President & Board Member
Hans Hull JD
Chief Business Officer
Dean Sheppard MD
Scientific Founder and Scientific Advisor, Translational Medicine
Barbara Howes
Chief Human Resources Officer
Éric Lefebvre MD
Chief Medical Officer
Hal Chapman MD
Scientific Founder and Scientific Advisor, Translational Medicine
Keith Cummings MD
Chief Financial Officer
Rik Derynck Ph.D
Scientific Co-Founder & Scientific Advisor of Biology
William DeGrado Ph.D
Scientific Founder

Board

John Curnutte MD
Neil Exter
Third Rock Ventures
Hoyoung Huh Ph.D
Kevin Raidy
Cowen Group
Suzanne Bruhn Ph.D
Craig Muir
Third Rock Ventures
Smital Shah
Charles Homcy MD
Third Rock Ventures

Pliant Therapeutics stock FAQs

plusminus

Can you buy Pliant Therapeutics stock?

You can no longer buy Pliant Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Pliant Therapeutics stock?

You can no longer buy Pliant Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Pliant Therapeutics stock?

You can no longer sell stock of Pliant Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Pliant Therapeutics stock?

You can no longer sell stock of Pliant Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Pliant Therapeutics a public company?

Pliant Therapeutics is now a public company traded on NASDAQ with ticker PLRX.
plusminus

What is Pliant Therapeutics’ stock price?

The stock price of Pliant Therapeutics is $16.51 as of 1/18/24.
plusminus

What is Pliant Therapeutics’ stock ticker symbol?

The ticker symbol of Pliant Therapeutics is PLRX.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Pliant Therapeutics News and Media Highlights

Novartis bets $80M on Pliant's preclinical NASH prospect

Novartis has put up $80 million to land the global license to Pliant Therapeutics’ preclinical nonalcoholic steatohepatitis (NASH) asset and three additional candidates. The NASH drug, PLN-1474, is a small molecule inhibitor of integrin αVβ1 Pliant thinks can reduce the growth of fibrotic tissue in the liver.
Browse Insights
Updated on: Dec 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.